This patent is a strategic one, to prevent others to "use midkine" for alopecia treatment. It is not currently used by Advangen which relies solely on FGF-5 for its Evolis and Jo-Ju products. The CEO, Head of Sc at the time (Darren) and an original team member of Adv Japan wrote that weak patent just to block any competitor. Midkine alone does not promote hair regrowth. It's good tactics. BUT this will never generate any direct value, royalties or else.
Patents where midkine has some value are all with Lyramid, and now for use by a Panama shell company for the benefit of cheesy companies. Go Roquefort. Go Provel(mare).
CDY Price at posting:
6.3¢ Sentiment: None Disclosure: Held
(20min delay)